Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

References

• Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists—an opportunity to improve outcomes. Nat Clin Pract Rheumatol. 2006;2:594–601.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleisch-mann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.
   Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of eta-nercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• van Riel PLCM, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheu-matoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis. 2006;65:1478–83.
   PubMedGoogle Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol. 2006;16:63–7.
   PubMedGoogle Scholar
• Kameda H, Sekiguchi N, Nagasawa H, Amano K, Takei H, Suzuki K, et al. Development and validation of handy rheu-matoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. Mod Rheumatol. 2006;16:381–8.
   PubMedGoogle Scholar
• Choy EH. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatology. 2004;43:1205–7.
   PubMedGoogle Scholar
• Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW, et al. Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt Study). Arthritis Rheum. 2005;52:3381–90.
   Google Scholar
• Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfa-salazine: a double-blind comparison. Ann Rheum Dis. 2006;65:1357–62.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheuma-toid arthritis. Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
   Google Scholar
• Kameda H, Amano K, Sekiguchi N, Takei H, Ogawa H, Nagasawa H, et al. Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod Rheumatol. 2004;14:442–6.
   PubMedGoogle Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis manage-ment group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.
   PubMedGoogle Scholar
• Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis manage-ment group in Japan: one-year clinical outcome (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruc-tion (RECONFIRM-2J). Mod Rheumatol. 2008;18:447–52.
   PubMed Web of Science ®Google Scholar
• Maini E, St clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DMFM, St. Claire EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.
   Google Scholar
• St. Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P. Combination of infliximab and metho-trexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more effica-cious. Arthritis Res Ther. 2003;5:R347–51.
   Google Scholar
• Hyrich KL, Symmons DPM, Watson KD, Silman AJ, on behalf of the British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept mono-therapy with response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheuma-toid arthritis. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:1786–94.
   Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
   Google Scholar
• Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, et al. The combination of etanercept and metho-trexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495–501.
   PubMed Web of Science ®Google Scholar